Linked Life Data

17673814

Source:http://linkedlifedata.com/resource/pubmed/id/17673814

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-8-3
pubmed:abstractText
We conducted a clinical pilot study to evaluate the efficacy and safety of the combination of docetaxel and 5'DFUR as a second-line chemotherapy for gastric cancer. Twenty-four patients were divided into two groups by simple randomization: group A (60 mg/m2 of docetaxel, every 3 wk) and group B (regimen A + 600 mg/body of 5'DFUR). The response rate was 17% and 42% in group A and B, respectively (p < 0.05). The MST from the start of the first-line was 17 mo in group B. The major adverse event was leukopenia in both groups.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1357-0560
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
71-5
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
A clinical study of docetaxel with or without 5'DFUR as a second-line chemotherapy for advanced gastric cancer.
pubmed:affiliation
Department of Surgery, Shinshu University School of Medicine, Japan. maruta@hsp.md.shinshu-u.ac.jp
pubmed:publicationType
Journal Article, Randomized Controlled Trial